Summary
Treating primary ‘negative symptoms’ of schizophrenia with a combination of a typical antipsychotic and a selective serotonin reuptake inhibitor, is more effective than with antipsychotic alone and is similar to the effect of the atypical antipsychotic, clozapine. The mechanism of this treatment combination is unknown and may involve changes in dopaminergic and serotonin systems. We studied dopamine and serotonin metabolism in different rat brain areas at 1.5 and 24 h after the last dosage of chronic treatment (30 days), with haloperidol plus fluvoxamine, each drug alone, and clozapine. Haloperidol-fluvoxamine combination, haloperidol, and clozapine treatments increased striatal and frontal cortex dopamine turnover and reduced striatal tyrosine hydroxylase activity at 1.5 h. At 24 h both dopamine turnover and tyrosine hydroxylase activity were reduced. Thus, in chronically treated animals, release of striatal dopamine increases following a drug pulse and returns to baseline by 24 h. Serotonin and 5-hydroxyindoleacetic acid concentrations were decreased at 1.5 h in haloperidol-fluvoxamine and clozapine groups and returned to normal levels by 24 h. A limited behavioral assessment showed that treatment with haloperidol plus fluvoxamine reduced motor activity compared to haloperidol, and increased sniffing compared to haloperidol, fluvoxamine and clozapine. These findings indicate that combining antipsychotic with SSRI results in specific changes in dopaminergic and serotonergic systems and in behavior. The possibility that these may be relevant to the mechanism underlying the clinical effectiveness of augmentation treatment warrant further study.
Similar content being viewed by others
References
BW Adams B Moghaddam (2001) ArticleTitleEffect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex Biol Psychiatry 50 750–757 Occurrence Handle11720693 Occurrence Handle10.1016/S0006-3223(01)01195-7 Occurrence Handle1:CAS:528:DC%2BD3MXosFKksr4%3D
Y Ago S Nakamura A Baba T Matsuda (2005) ArticleTitleSulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex Neuropsychopharmacology 30 43–51 Occurrence Handle15383832 Occurrence Handle10.1038/sj.npp.1300567 Occurrence Handle1:CAS:528:DC%2BD2cXhtVyisbvK
AR Ase F Amdiss C Hebert N Huang NM van Gelder TA Reader (1999) ArticleTitleEffects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors J Neural Transm 106 75–105 Occurrence Handle10195336 Occurrence Handle10.1007/s007020050142 Occurrence Handle1:CAS:528:DyaK1MXisVOltbs%3D
O Bai J Chlan-Fourney R Bowen D Keegan XM Li (2003) ArticleTitleExpression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs J Neurosci Res 71 127–131 Occurrence Handle12478621 Occurrence Handle10.1002/jnr.10440 Occurrence Handle1:CAS:528:DC%2BD3sXht1Ogtw%3D%3D
RJ Baldessarini F Centorrino JG Flood SA Volpicelli D Huston-Lyons BM Cohen (1993) ArticleTitleTissue concentrations of clozapine and its metabolites in the rat Neuropsychopharmacology 9 117–124 Occurrence Handle8216694 Occurrence Handle1:CAS:528:DyaK2cXpsVKlug%3D%3D
RJ Baldessarini ER Marsh NS Kula (1992) ArticleTitleInteractions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions Brain Res 579 152–156 Occurrence Handle1623401 Occurrence Handle10.1016/0006-8993(92)90754-W Occurrence Handle1:CAS:528:DyaK38XktVWls7w%3D
VN Barth E Chernet LJ Martin AB Need KS Rash M Morin LA Phebus (2006) ArticleTitleComparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer Life Sci 78 3007–3012 Occurrence Handle16434058 Occurrence Handle10.1016/j.lfs.2005.11.031 Occurrence Handle1:CAS:528:DC%2BD28XksVagsLs%3D
RH Belmaker (1984) ArticleTitleThe lessons of platelet monoamine oxidase Psychol Med 14 249–253 Occurrence Handle6539923 Occurrence Handle1:STN:280:DyaL2c3kvVCktA%3D%3D Occurrence Handle10.1017/S0033291700003512
FP Bymaster W Zhang PA Carter J Shaw E Chernet L Phebus DT Wong KW Perry (2002) ArticleTitleFluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex Psychopharmacology (Berl) 160 353–361 Occurrence Handle10.1007/s00213-001-0986-x Occurrence Handle1:CAS:528:DC%2BD38XktFGhsLs%3D
Y Chertkow O Weinreb MB Youdim H Silver (2005) ArticleTitleThe effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex Int J Neuropsychopharmacol 8 1–10 Occurrence Handle10.1017/S1461145704004936 Occurrence Handle1:CAS:528:DC%2BD2MXhtlersLo%3D
S Cho AM Duchemin NH Neff M Hadjiconstantinou (1999) ArticleTitleTyrosine hydroxylase, aromatic L-amino acid decarboxylase and dopamine metabolism after chronic treatment with dopaminergic drugs Brain Res 830 237–245 Occurrence Handle10366680 Occurrence Handle10.1016/S0006-8993(99)01395-5 Occurrence Handle1:CAS:528:DyaK1MXjtl2qsLY%3D
VZ Chong LT Young RK Mishra (2002) ArticleTitlecDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment J Neurochem 82 1533–1539 Occurrence Handle12354301 Occurrence Handle10.1046/j.1471-4159.2002.01104.x Occurrence Handle1:CAS:528:DC%2BD38XnsV2hsL8%3D
WA Daniel M Syrek J Wojcikowski (1999) ArticleTitleThe influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in the rat Eur Neuropsychopharmacol 9 337–344 Occurrence Handle10422895 Occurrence Handle10.1016/S0924-977X(99)00006-1 Occurrence Handle1:CAS:528:DyaK1MXksFWrs7s%3D
KL Davis RS Kahn G Ko M Davidson (1991) ArticleTitleDopamine in schizophrenia: a review and reconceptualization Am J Psychiatry 148 1474–1486 Occurrence Handle1681750 Occurrence Handle1:STN:280:DyaK38%2Fis1GksQ%3D%3D
D Denys AA Klompmakers HG Westenberg (2004) ArticleTitleSynergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine Psychopharmacology (Berl) 176 195–203 Occurrence Handle10.1007/s00213-004-1880-0 Occurrence Handle1:CAS:528:DC%2BD2cXoslSltbg%3D
G Di Chiara A Imperato (1985) ArticleTitleRapid tolerance to neuroleptic-induced stimulation of dopamine release in freely moving rats J Pharmacol Exp Ther 235 487–494 Occurrence Handle2865354 Occurrence Handle1:CAS:528:DyaL28XhsV2gsA%3D%3D
PR Dunkley L Bobrovskaya ME Graham EI von Nagy-Felsobuki PW Dickson (2004) ArticleTitleTyrosine hydroxylase phosphorylation: regulation and consequences J Neurochem 91 1025–1043 Occurrence Handle15569247 Occurrence Handle10.1111/j.1471-4159.2004.02797.x Occurrence Handle1:CAS:528:DC%2BD2cXhtFSisbfO
EC Essig IC Kilpatrick (1991) ArticleTitleInfluence of acute and chronic haloperidol treatment on dopamine metabolism in the rat caudate-putamen, prefrontal cortex and amygdala Psychopharmacology (Berl) 104 194–200 Occurrence Handle10.1007/BF02244178 Occurrence Handle1:CAS:528:DyaK3MXkvVGht78%3D
CR Estrella C Bregonzio RJ Cabrera (2002) ArticleTitleDifferential responses in central dopaminergic activity induced by apomorphine in IPL nude rat Behav Brain Res 133 143–148 Occurrence Handle12110447 Occurrence Handle10.1016/S0166-4328(01)00467-3 Occurrence Handle1:CAS:528:DC%2BD38XltV2qt7Y%3D
JM Finlay A Jakubovic DS Fu HC Fibiger (1987) ArticleTitleTolerance to haloperidol-induced increases in dopamine metabolites: fact or artifact? Eur J Pharmacol 137 117–121 Occurrence Handle3609130 Occurrence Handle10.1016/0014-2999(87)90189-0 Occurrence Handle1:CAS:528:DyaL2sXktleisb0%3D
V Fischer U Schmitt H Weigmann B Von Keller S Reuss C Hiemke N Dahmen (1998) ArticleTitleChronical haloperidol and clozapine treatment in rats: differential RNA display analysis, behavioral studies and serum level determination Prog Neuropsychopharmacol Biol Psychiatry 22 1129–1139 Occurrence Handle9829293 Occurrence Handle10.1016/S0278-5846(98)00065-7 Occurrence Handle1:CAS:528:DyaK1cXnt1Kks7g%3D
XM Gao T Hashimoto TB Cooper CA Tamminga (1997) ArticleTitleThe dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration J Neural Transm 104 97–104 Occurrence Handle9085197 Occurrence Handle10.1007/BF01271298 Occurrence Handle1:CAS:528:DyaK2sXis1ehsrw%3D
DC Goff KK Midha O Sarid-Segal JW Hubbard E Amico (1995) ArticleTitleA placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia Psychopharmacology (Berl) 117 417–423 Occurrence Handle10.1007/BF02246213 Occurrence Handle1:CAS:528:DyaK2MXlt1Ortrg%3D
AA Grace BS Bunney H Moore CL Todd (1997) ArticleTitleDopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs Trends Neurosci 20 31–37 Occurrence Handle9004417 Occurrence Handle10.1016/S0166-2236(96)10064-3 Occurrence Handle1:CAS:528:DyaK2sXhtlOrsA%3D%3D
K Hakansson L Pozzi A Usiello J Haycock E Borrelli G Fisone (2004) ArticleTitleRegulation of striatal tyrosine hydroxylase phosphorylation by acute and chronic haloperidol Eur J Neurosci 20 1108–1112 Occurrence Handle15305880 Occurrence Handle10.1111/j.1460-9568.2004.03547.x
LM Hall GM Anderson DJ Cohen (1995) ArticleTitleAcute and chronic effects of fluoxetine and haloperidol on mouse brain serotonin and norepinephrine turnover Life Sci 57 791–801 Occurrence Handle7543647 Occurrence Handle10.1016/0024-3205(95)02007-6 Occurrence Handle1:CAS:528:DyaK2MXmvFOru7c%3D
S Hartter H Wetzel E Hammes M Torkzadeh C Hiemke (1998) ArticleTitleSerum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial Pharmacopsychiatry 31 199–200 Occurrence Handle9832352 Occurrence Handle1:CAS:528:DyaK1MXht1Wktg%3D%3D
S Hartter H Wetzel C Hiemke (1992) ArticleTitleAutomated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography Clin Chem 38 2082–2086 Occurrence Handle1394994 Occurrence Handle1:STN:280:DyaK3s%2FgvV2lsw%3D%3D
JJ Hoo P Noldt WJ Beckermann DP Agarwal HW Goedde (1982) ArticleTitleIn vitro effect of haloperidol, chlorpromazine, imipramine and lithium on the erythrocyte catechol-O-methyltransferase Arzneimittelforschung 32 681–683 Occurrence Handle7202372 Occurrence Handle1:CAS:528:DyaL38Xks1Khu7Y%3D
J Ichikawa HY Meltzer (1991) ArticleTitleDifferential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens J Pharmacol Exp Ther 256 348–357 Occurrence Handle1703232 Occurrence Handle1:CAS:528:DyaK3MXpsFSmug%3D%3D
K Igarashi F Kasuya M Fukui E Usuki N Castagnoli SuffixJr (1995) ArticleTitleStudies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP Life Sci 57 2439–2446 Occurrence Handle8847965 Occurrence Handle10.1016/0024-3205(95)02240-5 Occurrence Handle1:CAS:528:DyaK2MXpsFemsbY%3D
PW Kalivas P Duffy LA DuMars C Skinner (1988) ArticleTitleBehavioral and neurochemical effects of acute and daily cocaine administration in rats J Pharmacol Exp Ther 245 485–492 Occurrence Handle3130474 Occurrence Handle1:CAS:528:DyaL1cXktlWqtLY%3D
B Karolewicz L Antkiewicz-Michaluk J Michaluk J Vetulani (1996) ArticleTitleDifferent effects of chronic administration of haloperidol and pimozide on dopamine metabolism in the rat brain Eur J Pharmacol 313 181–186 Occurrence Handle8911913 Occurrence Handle10.1016/0014-2999(96)00451-7 Occurrence Handle1:CAS:528:DyaK28XmtV2jtLs%3D
T Kato S Horiuchi A Togari T Nagatsu (1981) ArticleTitleA sensitive and inexpensive high-performance liquid chromatographic assay for tyrosine hydroxylase Experientia 37 809–811 Occurrence Handle6116611 Occurrence Handle10.1007/BF01985652 Occurrence Handle1:CAS:528:DyaL3MXlt1yjsrc%3D
S Koch KW Perry FP Bymaster (2004) ArticleTitleBrain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat Neuropharmacology 46 232–242 Occurrence Handle14680761 Occurrence Handle10.1016/j.neuropharm.2003.09.001 Occurrence Handle1:CAS:528:DC%2BD3sXpvVWgsLw%3D
SC Kumer KE Vrana (1996) ArticleTitleIntricate regulation of tyrosine hydroxylase activity and gene expression J Neurochem 67 443–462 Occurrence Handle8764568 Occurrence Handle1:CAS:528:DyaK28XksFCjsLo%3D Occurrence Handle10.1046/j.1471-4159.1996.67020443.x
M Kurachi R Shibata M Murata Y Tanii (1995) ArticleTitleParallel development of dopamine metabolism tolerance in the rat prefrontal cortex, caudate-putamen, and amygdala following haloperidol decanoate administration Biol Psychiatry 37 487–490 Occurrence Handle7786966 Occurrence Handle10.1016/0006-3223(94)00327-Y Occurrence Handle1:CAS:528:DyaK2MXls1Kmt7g%3D
T Kuroki HY Meltzer J Ichikawa (1999) ArticleTitleEffects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens J Pharmacol Exp Ther 288 774–781 Occurrence Handle9918588 Occurrence Handle1:CAS:528:DyaK1MXpvFOmuw%3D%3D
JA Lieberman TS Stroup JP McEvoy MS Swartz RA Rosenheck DO Perkins RS Keefe SM Davis CE Davis BD Lebowitz J Severe JK Hsiao (2005) ArticleTitleEffectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 1209–1223 Occurrence Handle16172203 Occurrence Handle10.1056/NEJMoa051688 Occurrence Handle1:CAS:528:DC%2BD2MXhtVeltL%2FN
HY Meltzer Z Li Y Kaneda J Ichikawa (2003) ArticleTitleSerotonin receptors: their key role in drugs to treat schizophrenia Prog Neuropsychopharmacol Biol Psychiatry 27 1159–1172 Occurrence Handle14642974 Occurrence Handle10.1016/j.pnpbp.2003.09.010 Occurrence Handle1:CAS:528:DC%2BD3sXpt1SgtLg%3D
H Moore AA Grace (2002) ArticleTitleA role for electrotonic coupling in the striatum in the expression of dopamine receptor-mediated stereotypies Neuropsychopharmacology 27 980–992 Occurrence Handle12464455 Occurrence Handle10.1016/S0893-133X(02)00383-4 Occurrence Handle1:CAS:528:DC%2BD38XptFKis7o%3D
C Moret M Briley (1992) ArticleTitleEffect of antidepressant drugs on monoamine synthesis in brain in vivo Neuropharmacology 31 679–684 Occurrence Handle1357575 Occurrence Handle10.1016/0028-3908(92)90146-G Occurrence Handle1:CAS:528:DyaK38XkvVegtb4%3D
BP Murphy YC Chung TW Park PD McGorry (2006) ArticleTitlePharmacological treatment of primary negative symptoms in schizophrenia: A systematic review Schizophr Res 88 5–25 Occurrence Handle16930948 Occurrence Handle10.1016/j.schres.2006.07.002
NK Ng HS Lee PT Wong (1999) ArticleTitleRegulation of striatal dopamine release through 5-HT1 and 5-HT2 receptors J Neurosci Res 55 600–607 Occurrence Handle10082082 Occurrence Handle10.1002/(SICI)1097-4547(19990301)55:5<600::AID-JNR7>3.0.CO;2-# Occurrence Handle1:CAS:528:DyaK1MXhsFOktr8%3D
A Ortega-Alvaro J Gibert-Rahola JA Mico (2006) ArticleTitleInfluence of chronic treatment with olanzapine, clozapine and scopolamine on performance of a learned 8-arm radial maze task in rats Prog Neuropsychopharmacol Biol Psychiatry 30 104–111 Occurrence Handle16226364 Occurrence Handle10.1016/j.pnpbp.2005.08.020 Occurrence Handle1:CAS:528:DC%2BD2MXhtlGls7rI
J Penttila J Kajander S Aalto J Hirvonen K Nagren T Ilonen E Syvalahti J Hietala (2004) ArticleTitleEffects of fluoxetine on dopamine D2 receptors in the human brain: a positron emission tomography study with [11C]raclopride Int J Neuropsychopharmacol 7 431–439 Occurrence Handle15315717 Occurrence Handle10.1017/S146114570400450X Occurrence Handle1:CAS:528:DC%2BD2cXpsVOqsrg%3D
PJ Perry DD Miller SV Arndt RJ Cadoret (1991) ArticleTitleClozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients Am J Psychiatry 148 231–235 Occurrence Handle1670979 Occurrence Handle1:STN:280:DyaK3M7gtlenuw%3D%3D
SC Piscitelli JA Frazier K McKenna KE Albus DR Grothe CT Gordon JL Rapoport (1994) ArticleTitlePlasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response J Clin Psychiatry 55 IssueIDSuppl B 94–97 Occurrence Handle7961584
M Rapoport R van Reekum H Mayberg (2000) ArticleTitleThe role of the cerebellum in cognition and behavior: a selective review J Neuropsychiatry Clin Neurosci 12 193–198 Occurrence Handle11001597 Occurrence Handle1:STN:280:DC%2BD3cvjtlSrtQ%3D%3D
RB Rastogi RL Singhal YD Lapierre (1982) ArticleTitleComparative effects of short- and long-term treatment with neuroleptics on behavioural activity as well as dopamine turnover in striatum Gen Pharmacol 13 35–40 Occurrence Handle6120880 Occurrence Handle1:CAS:528:DyaL38XhtlGktb0%3D
B Scatton (1977) ArticleTitleDifferential regional development of tolerance to increase in dopamine turnover upon repeated neuroleptic administration Eur J Pharmacol 46 363–369 Occurrence Handle590344 Occurrence Handle10.1016/0014-2999(77)90230-8 Occurrence Handle1:CAS:528:DyaE1cXhtFGgsrg%3D
U Schmitt N Dahmen V Fischer H Weigmann ML Rao S Reuss C Hiemke (1999) ArticleTitleChronic oral haloperidol and clozapine in rats: a behavioral evaluation Neuropsychobiology 39 86–91 Occurrence Handle10072665 Occurrence Handle10.1159/000026566 Occurrence Handle1:CAS:528:DyaK1MXit1Krt7g%3D
P Schulte (2003) ArticleTitleWhat is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia Clin Pharmacokinet 42 607–618 Occurrence Handle12844323 Occurrence Handle10.2165/00003088-200342070-00001 Occurrence Handle1:CAS:528:DC%2BD3sXmvFShsL4%3D
H Silver N Aharon A Kaplan (2003) ArticleTitleAdd-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms Schizophr Bull 29 541–546 Occurrence Handle14609247
H Silver I Barash N Aharon A Kaplan M Poyurovsky (2000) ArticleTitleFluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study Int Clin Psychopharmacol 15 257–261 Occurrence Handle10993127 Occurrence Handle1:STN:280:DC%2BD3cvktlSgtQ%3D%3D Occurrence Handle10.1097/00004850-200015050-00002
H Silver M Kushnir A Kaplan (1996) ArticleTitleFluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study Biol Psychiatry 40 671–674 Occurrence Handle8886304 Occurrence Handle10.1016/0006-3223(96)00170-9 Occurrence Handle1:CAS:528:DyaK28XmsFWns7Y%3D
H Silver A Nassar (1992) ArticleTitleFluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study Biol Psychiatry 31 698–704 Occurrence Handle1599987 Occurrence Handle10.1016/0006-3223(92)90279-9 Occurrence Handle1:STN:280:DyaK383ovVSlsw%3D%3D
H Silver N Shmugliakov (1998) ArticleTitleAugmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study J Clin Psychopharmacol 18 208–211 Occurrence Handle9617979 Occurrence Handle10.1097/00004714-199806000-00005 Occurrence Handle1:CAS:528:DyaK1cXjsVOmu78%3D
H Silver MB Youdim (2000) ArticleTitleMAO-A and MAO-B activities in rat striatum, frontal cortex and liver are unaltered after long-term treatment with fluvoxamine and desipramine Eur Neuropsychopharmacol 10 125–128 Occurrence Handle10706994 Occurrence Handle10.1016/S0924-977X(99)00066-8 Occurrence Handle1:CAS:528:DC%2BD3cXhsFGksrw%3D
P Smid HK Coolen HG Keizer R van Hes JP de Moes AP den Hartog B Stork RH Plekkenpol LC Niemann CN Stroomer MT Tulp HH van Stuivenberg AC McCreary MB Hesselink AH Herremans CG Kruse (2005) ArticleTitleSynthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition J Med Chem 48 6855–6869 Occurrence Handle16250644 Occurrence Handle10.1021/jm050148z Occurrence Handle1:CAS:528:DC%2BD2MXhtVGqsr3E
E Spina P De Domenico C Ruello N Longobardo C Gitto M Ancione AE Di Rosa AP Caputi (1994) ArticleTitleAdjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients Int Clin Psychopharmacol 9 281–285 Occurrence Handle7868850 Occurrence Handle10.1097/00004850-199400940-00007 Occurrence Handle1:STN:280:DyaK2M7ntlektw%3D%3D
T Sumiyoshi H Kido H Sakamoto K Urasaki K Suzuki N Yamaguchi H Mori K Shiba (1994) ArticleTitleTime course of dopamine1,2 and serotonin2 receptor binding of antipsychotics in vivo Pharmacol Biochem Behav 49 165–169 Occurrence Handle7816868 Occurrence Handle10.1016/0091-3057(94)90471-5 Occurrence Handle1:CAS:528:DyaK2cXlslSnt74%3D
H Tokunaga K Kudo T Imamura N Jitsufuchi Y Ohtsuka N Ikeda (1997) ArticleTitlePlasma concentrations of antipsychotic drugs in psychiatric inpatients Nippon Hoigaku Zasshi 51 417–422 Occurrence Handle9545754 Occurrence Handle1:STN:280:DyaK1c3gsleltg%3D%3D
M Toru M Takashima (1985) ArticleTitleHaloperidol in large doses reduces the cataleptic response and increases noradrenaline metabolism in the brain of the rat Neuropharmacology 24 231–236 Occurrence Handle4039420 Occurrence Handle10.1016/0028-3908(85)90079-6 Occurrence Handle1:CAS:528:DyaL2MXhvFOqtrc%3D
SM Vasconcelos VS Nascimento CR Nogueira CM Vieira FC Sousa MM Fonteles GS Viana (2003) ArticleTitleEffects of haloperidol on rat behavior and density of dopaminergic D2-like receptors Behav Processes 63 45–52 Occurrence Handle12763267 Occurrence Handle10.1016/S0376-6357(03)00028-7
PC Waldmeier (1979) ArticleTitleAnalysis of the activation of dopamine metabolism by a serotonin uptake inhibitor Eur J Pharmacol 60 315–322 Occurrence Handle527667 Occurrence Handle10.1016/0014-2999(79)90235-8 Occurrence Handle1:CAS:528:DyaL3cXht1WrsLo%3D
PC Waldmeier AA Delini-Stula (1979) ArticleTitleSerotonin – dopamine interactions in the nigrostriatal system Eur J Pharmacol 55 363–373 Occurrence Handle572774 Occurrence Handle10.1016/0014-2999(79)90110-9 Occurrence Handle1:CAS:528:DyaE1MXkslamsrw%3D
PC Waldmeier L Maitre (1976) ArticleTitleClozapine: reduction of the initial dopamine turnover increase by repeated treatment Eur J Pharmacol 38 197–203 Occurrence Handle954831 Occurrence Handle10.1016/0014-2999(76)90219-3 Occurrence Handle1:CAS:528:DyaE28XltFKks70%3D
H Weigmann S Hartter S Maehrlein W Kiefer G Kramer G Dannhardt C Hiemke (2001) ArticleTitleSimultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography J Chromatogr B Biomed Sci Appl 759 63–71 Occurrence Handle11499630 Occurrence Handle10.1016/S0378-4347(01)00215-8 Occurrence Handle1:CAS:528:DC%2BD3MXks1Oiuro%3D
DT Wong FP Bymaster LR Reid PG Threlkeld (1983) ArticleTitleFluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors Biochem Pharmacol 32 1287–1293 Occurrence Handle6303355 Occurrence Handle10.1016/0006-2952(83)90284-8 Occurrence Handle1:CAS:528:DyaL3sXktlejsb0%3D
G Zernig H De Wit S Telser M Nienhusmeier G Wakonigg K Sturm I Berger G Kemmler A Saria (2004) ArticleTitleSubjective effects of slow-release bupropion versus caffeine as determined in a quasi-naturalistic setting Pharmacology 70 206–215 Occurrence Handle15001822 Occurrence Handle10.1159/000075550 Occurrence Handle1:CAS:528:DC%2BD2cXhsl2gs7c%3D
W Zhang KW Perry DT Wong BD Potts J Bao GD Tollefson FP Bymaster (2000) ArticleTitleSynergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex Neuropsychopharmacology 23 250–262 Occurrence Handle10942849 Occurrence Handle10.1016/S0893-133X(00)00119-6 Occurrence Handle1:CAS:528:DC%2BD3cXls1Gisrs%3D
Author information
Authors and Affiliations
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s00702-007-0782-9.
Rights and permissions
About this article
Cite this article
Chertkow, Y., Weinreb, O., Youdim, M. et al. Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment. J Neural Transm 114, 1443–1454 (2007). https://doi.org/10.1007/s00702-007-0753-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-007-0753-1